Table E.2.
Range in 2014 (in mg/PCU) | Changes in sales 2011–2014 in individual countries) (in mg/PCU)a | No of countries where sales decreased 2011–2014a | No of countries where sales increased 2011–2014a | |
---|---|---|---|---|
Overall sales | 3.1–418.8 | From −62.23 to +82.97 | 14 | 11 |
Sales of 3rd‐ and 4th‐generation cephalosporins | 0.0004–0.79 | From −0.2 to +0.62 | 10 | 15 |
Sales of fluoroquinolones | 0.004–11.38 | From −3.17 to +2.99 | 11 | 14 |
Sales of all quinolones | 0.004–11.55 | From −4.24 to +5.49 | 14 | 11 |
Sales of polymyxinsb | 0.06–36.1 | From −2.67 to +9.67 | 13 | 9 |
Corrections in sales data and/or PCU data published in 2012 are described in Chapter 1.5 of the seventh ESVAC report.
PCU: population correction unit.
Only countries for which 2011–2014 data are available are included.
For polymyxins data is from 22 countries as polymyxins were not sold in three countries reporting in 2011–2014.